Stay updated on Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.

Latest updates to the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedMinor site maintenance updates were applied: Revision v3.4.2 added and the earlier notices (including Revision v3.4.1) removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about funding status and operating status was added, and the release notes show Revision: v3.4.1. These updates do not alter the study content or its reported information.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a Show glossary option and updated the QC-related labels to reflect the latest revision (Last Update Submitted that Met QC Criteria and Revision: v3.4.0), while older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4) were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing the previous Revision: v3.3.3. This is a metadata version update and does not modify study content or eligibility criteria.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section that includes Maryland and New York. Removed the separate Maryland Locations and New York Locations sections, and updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check91 days agoChange DetectedAdded a note in Publications indicating that publications are provided voluntarily and pertain to study results. Updated the revision tag to Revision: v3.3.2 and removed the older Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.